Dr. Reddy’s Laboratories (DRREDDY) Investor presentation summary

Company overview and performance

• Operates in 76 countries with a workforce representing 53 nationalities and 26,000+ employees.

• Reached 704 million patients globally, generating $3.35 billion in revenue with 14% growth and ~30% EBITDA margin in FY24.

• Maintains 31 manufacturing and R&D plants, with a focus on affordable and innovative medicines.

• Achieved ~36% ROCE and sustained double-digit revenue growth.

• Recognized for sustainability and gender equality, included in Dow Jones Sustainability World Index and Bloomberg Gender-Equality Index.

Strategic priorities and business model

• Strategy centers on strengthening core businesses (generics, biosimilars, API) and investing in future growth areas (biologics, digital, D2C, nutraceuticals).

• Aims to serve 1.5 billion+ patients, deliver double-digit revenue growth, and maintain 25%+ EBITDA and ROCE.

• Execution driven by market leadership, productivity (digital, automation, operational excellence), and patient-focused innovation.

• Focus on quality, compliance, operational efficiency, and integrating ESG into business.

Segment and geographic performance

• FY24 revenue: ₹27,916 Cr, with 88% from global generics, 11% from pharmaceutical services & active ingredients (PSAI), and 1% from others.

• North America: #8 US generics player, 230+ commercial products, 20 new launches, and expansion into OTC wellness.

• India: 14 brands in top 300, #2 vaccine player, 13 new launches, and entry into digital therapeutics.

• Emerging markets: Present in 47 markets, 106 new launches, focus on mega-brands and differentiated formulations.

• Europe: 18 markets, 180+ products, 42 new launches, entry into consumer health and digital therapeutics.